New Jersey Urology Adds Dr. Chidebelu Ufodike as Chief Operating Officer

New Jersey Urology is pleased to announce the appointment of nationally recognized healthcare leader Dr. Chidebelu Ufodike as Chief Operating Officer. Dr. Ufodike has more than 25 years of experience across healthcare operations, pharmacy and integrated care delivery leading large-scale operational initiatives.

New Jersey Urology spans more than 20 locations throughout the central and southern regions of the state and is a leading provider of urology and cancer care services, bringing the latest treatments and technologies to the community. New Jersey Urology is an affiliate of U.S. Urology Partners, a partner to community-based practices that is backed by General Atlantic.

Dr. Gordon A. Brown, New Jersey Urology, stated, “We are excited about the addition of Dr. Chidebulu Ufodike to our leadership team. As a recognized leader in managing complex healthcare delivery models alongside his passion for operational excellence, we consider Dr. Ufodike to be a perfect addition to our team at New Jersey Urology. His focus on preserving excellent patient outcomes while expanding access to novel services lines will allow New Jersey Urology to continue to provide the best-in-class care to our patients across the region.”

Dr. Chidebelu Ufodike stated, “I’m excited to join New Jersey Urology and partner with such an exceptional group of physicians and healthcare professionals who are deeply committed to delivering high-quality, patient-centered care. The organization has built a strong reputation for clinical excellence across the region, and I look forward to working alongside the leadership team to strengthen operations, expand access to care and support the continued growth of this outstanding practice.”

“Throughout my career I’ve focused on building scalable operating models that allow physicians to focus on delivering outstanding care to patients. I’m excited to help further strengthen the infrastructure and capabilities that will support New Jersey Urology’s physicians and ensure the organization continues to thrive as a leading urology platform,” said Dr. Ufodike.

Dr. Ufodike previously served as Vice President of Pharmacy Inventory Management and Working Capital at Walgreens Boots Alliance, where he led enterprise initiatives supporting pharmacy operations across more than 8,000 locations nationwide. He was responsible for optimizing inventory strategy, improving working capital performance, strengthening supply chain capabilities and managing more than $75 billion in pharmacy inventory across one of the nation’s largest healthcare retail networks.

Earlier in his tenure at Walgreens, Dr. Ufodike played a key leadership role in one of the largest retail healthcare integrations in the United States, helping lead the operational integration of 1,934 acquired Rite Aid locations across 25 states representing approximately $19 billion in revenue into the Walgreens operating platform. He was also part of the leadership team that helped launch Walgreens Health, the company’s integrated healthcare services platform designed to expand access to physician-led care and value-based services, and supported the integration of newly acquired healthcare businesses including CareCentrix and Shields Health Solutions.

Dr. Ufodike earned his Doctor of Pharmacy degree from Howard University and his Bachelor of Pharmacy from the University of Nigeria. He is a member of the Beta Sigma Fraternity and has been recognized by the National Healthcare Coalition as one of the Top 100 Healthcare Executives of African Descent. He has also been featured in CXO Magazine’s “Most Admired Leaders in Healthcare.”

About New Jersey Urology

For decades, New Jersey Urology has been well-known for its leadership in the region, providing high-quality, compassionate care in more than 20 convenient locations across the state along with expert clinical research capabilities. Using the latest technology, the experienced team treats the full range of urologic conditions and cancers for men, women and children. New Jersey Urology ranks among the top practices nationwide, and our board-certified physicians and surgeons offer more than 50 specialties and subspecialities. Our depth of experience, combined with access to the latest advances in medical technology, help us deliver care that sets the standard for quality in the region. New Jersey Urology’s clinical network of offices spans these counties: Atlantic, Bucks (PA), Burlington, Camden, Cumberland, Gloucester, Mercer, Middlesex, Monmouth and Somerset. To learn more, visit www.njurology.com.

About U.S. Urology Partners

U.S. Urology Partners offers a comprehensive suite of practice management capabilities to its affiliated community-based urology practices, which maintain their local brand and identity that they have established, often over decades. U.S. Urology Partners currently supports six affiliated groups across a network of more than 70 locations in Florida, Indiana, Massachusetts, New Jersey, New York, Pennsylvania and Ohio. For more information, visit www.us-uro.com.

 

U.S. Urology Partners Adds Russ Adkins as Chief Legal Officer

U.S. Urology Partners today announced that Russ Adkins has joined its leadership team as Chief Legal Officer, supporting the company’s continued rapid growth. As a partner to independent, community-based urology practices, U.S. Urology Partners enables them to focus on delivering premier care to the patients they serve and is backed by leading global investor General Atlantic.

Corina Tracy, Chief Executive Officer of U.S. Urology Partners, stated, “We are excited to welcome Russ Adkins to the U.S. Urology Partners team. His extensive legal and healthcare experience will be of great value to U.S. Urology Partners as we continue to expand our best-in-class integrated healthcare platform within new and existing markets. Russ will help U.S. Urology Partners fulfill its core purpose and ambition of uniting high-performing, growth-oriented urology practices to provide the most efficient, effective and innovative urologic care to people in the communities we serve.”

Adkins has more than two decades of legal, compliance and healthcare experience, including corporate and business matters, mergers and acquisitions, regulatory, compliance and health law. He counsels the organization on health care, regulatory, strategic transactions, litigation, and operational and corporate governance matters.

Russ Adkins, Chief Legal Officer of U.S. Urology Partners, stated, “U.S. Urology Partners presents such a compelling opportunity for its associates and patients—allowing for expanded access to high quality, compassionate urology services from independent, community-based practices. I am thrilled and honored to join a company and management team of this caliber. I am humbled by the growth and scale U.S. Urology Partners has already achieved and look forward to being part of the transformation and growth of the future.”

Before joining U.S. Urology Partners, Adkins served nearly 13 years as Chief Legal Officer of Compassus, a Nashville-based leading provider of post-acute services. During his tenure at Compassus, Adkins helped scale the business and legal and compliance departments through tremendous growth, which included three private equity sponsorships, two recapitalizations, and dozens of platform acquisitions and joint ventures. Adkins also served as Chief Compliance Officer for Compassus for much of his tenure.

Prior to Compassus, Adkins served as the Vice President, Legal, for M*Modal Inc. (formerly MedQuist and Spheris), a leading global outsourcing provider of clinical documentation technology and services. He also served as associate general counsel while at Spheris. Prior to moving in-house, Adkins practiced law for private firms located in Boulder, Colorado, and Nashville, Tennessee. Adkins earned his law degree from the University of Louisville School of Law and has a master’s degree in law from New York University School of Law.

U.S. Urology Partners helps urology practices of all sizes retain independence and deliver quality care while practicing medicine in their preferred community-based setting. The company supports its affiliated groups with deep expertise in business operations, data insights and technology infrastructure to drive improved patient outcomes and satisfaction and to alleviate the substantial administrative burdens that lead to burnout for many providers. U.S. Urology Partners also invests in end-to-end clinical capabilities for cutting-edge genitourinary oncology – primarily cancer of the prostate, kidney and bladder – and non-oncology treatment pathways.

More detailed information about the U.S. Urology Partners leadership team can be found at www.us-uro.com/our-team.

About U.S. Urology Partners

U.S. Urology Partners offers a comprehensive suite of practice management capabilities to its affiliated community-based urology practices, which maintain their local brand and identity that they have established, often over decades. U.S. Urology Partners currently supports six affiliated groups across a network of more than 70 locations in Florida, Indiana, Massachusetts, New Jersey, New York, Pennsylvania and Ohio. For more information, please visit www.us-uro.com.

Dr. Marc Zeffren Joins New Jersey Urology

New Jersey Urology is pleased to announce that Marc Zeffren, M.D., has joined the practice. Dr. Zeffren is a urologist specializing in the management of urologic stone disease, benign prostatic hyperplasia (BPH) and urologic malignancies, with a particular focus on minimally invasive surgical treatment of renal masses and prostate cancer.

New Jersey Urology spans more than 20 locations throughout the central and southern regions of the state and is a leading provider of urology and cancer care services, bringing the latest treatments and technologies to the community. New Jersey Urology is an affiliate of U.S. Urology Partners, a partner to community-based practices that is backed by General Atlantic.

Dr. Gordon A. Brown, New Jersey Urology, stated, “Dr. Marc Zeffren is an excellent addition to the New Jersey Urology team. His patient-centered approach to care and surgical skill set will help us continue to provide best-in-class urologic care to our patients throughout New Jersey.”

Dr. Marc Zeffren stated, “I am passionate about community-based medicine and am excited for the opportunity to provide advanced urologic specialty care at New Jersey Urology to the greater South Jersey community. My philosophy of patient care is grounded in patient education, shared decision-making and high-quality execution. I aim to ensure patients understand their condition, guide them toward a treatment plan that aligns with their individual needs and healthcare goals, and provide care that results in excellent medical and surgical outcomes.”

Dr. Zeffren works closely with referring providers and said, “I look forward to supporting referring providers in the community through comprehensive management of urologic stone disease, BPH and urologic malignancies, with an emphasis on minimally invasive surgical approaches. I provide efficient evaluation, evidence-based decision-making and thoughtful procedural selection for renal masses and prostate cancer, while maintaining clear communication and timely feedback to referring providers to ensure seamless continuity of care.”

Originally from St. Louis, Dr. Zeffren relocated to the Northeast for his undergraduate and medical education. He earned his undergraduate degree from Lander College for Men in Queens, New York, and completed his medical degree at New York Medical College in Valhalla, New York. He went on to complete his urology residency at Cooper University Health Care in Camden, New Jersey, where he remained as an attending urologist and was actively involved in resident education and surgical training while maintaining a robust clinical practice.

New Jersey Urology has more than 20 medical offices throughout in these counties: Atlantic, Bucks (PA), Burlington, Camden, Cumberland, Gloucester, Mercer, Middlesex, Monmouth and Somerset.

To learn more about Dr. Zeffren or schedule an appointment, visit www.njurology.com/providers/marc-zeffren or call (877) 388-2778. Dr. Zeffren will primarily serve patients in the Linwood and Vineland offices.

About New Jersey Urology

For decades, New Jersey Urology has been well-known for its leadership in the region, providing high-quality, compassionate care in more than 20 convenient locations across the state along with expert clinical research capabilities. Using the latest technology, the experienced team treats the full range of urologic conditions and cancers for men, women and children. New Jersey Urology ranks among the top practices nationwide, and our board-certified physicians and surgeons offer more than 50 specialties and subspecialities. Our depth of experience, combined with access to the latest advances in medical technology, help us deliver care that sets the standard for quality in the region. New Jersey Urology’s clinical network of offices spans these counties: Atlantic, Bucks (PA), Burlington, Camden, Cumberland, Gloucester, Mercer, Middlesex, Monmouth and Somerset. For more information, visit www.njurology.com.

About U.S. Urology Partners

U.S. Urology Partners offers a comprehensive suite of practice management capabilities to its affiliated community-based urology practices, which maintain their local brand and identity that they have established, often over decades. U.S. Urology Partners currently supports six affiliated groups across a network of more than 70 locations in Florida, Indiana, Massachusetts, New Jersey, New York, Pennsylvania and Ohio. For more information, visit www.us-uro.com.

Nationally Recognized Urologist Melanie M. McNally, M.D. Returns to Associated Medical Professionals of NY

Associated Medical Professionals of NY (AMP) is pleased to announce that Melanie M. McNally, M.D., a beloved urologist who served patients at AMP for many years is returning to the practice. Dr. McNally has practiced as a general urologist since 2002 and brings more than 25 years of medical experience to AMP.

Associated Medical Professionals of NY spans 18 locations in Central New York, including eight offices and 13 hospitals. AMP is the region’s leading provider of urology and cancer care services, bringing the latest treatments and technologies to the community. AMP is an affiliate of U.S. Urology Partners, a partner to independent, community-based urology practices that is backed by General Atlantic.

Christopher M. Pieczonka, M.D., Chief Executive Officer of Associated Medical Professionals of NY, stated, “The residents of the Central New York are the real winners with Dr. Melanie McNally rejoining Associated Medical Professionals. It is a real home run to have such an experienced physician return to work with Associated Medical Professionals full time.”

Melanie M. McNally, M.D., stated, “I am excited to serve patients at Associated Medical Professionals of NY again and enjoy the collaborative atmosphere among highly skilled physicians with expertise in multiple subspecialities of urology. I am passionate about using the advanced technologies at AMP to address complex clinical challenges and value the integration of surgical skill with thoughtful medical decision-making. I believe a successful outcome is not only clinical improvement but also patient understanding, confidence and peace of mind.”

Dr. McNally cares for a wide range of general urology conditions with an emphasis on neuro-urology, kidney stones, overactive bladder and urinary incontinence. She has extensive experience performing bladder Botox treatments, PTNS (percutaneous tibial nerve stimulation) and sacral neuromodulation.

Dr. McNally earned her medical degree from the State University of New York at Buffalo School of Medicine and Biomedical Sciences and completed her urology residency at the University of Rochester School of Medicine. Her career spans diverse clinical settings, from a Level I Trauma Center to rural hospitals.

To learn more about Dr. McNally and AMP or to schedule an appointment, please visit www.ampofny.com or call (315) 478-4185. Dr. McNally will primarily be serving patients in the Auburn and Camillus locations.

About U.S. Urology Partners

U.S. Urology Partners offers a comprehensive suite of practice management capabilities to its affiliated community-based urology practices, which maintain their local brand and identity that they have established, often over decades. U.S. Urology Partners currently supports six affiliated groups across a network of more than 70 locations in Florida, Indiana, Massachusetts, New York, New Jersey, Pennsylvania and Ohio. For more information, please visit www.us-uro.com.

Virtuoso Surgical Adds Healthcare Innovator Rob Waggener to Board of Directors

Virtuoso Surgical, Inc., a Nashville-based company developing a groundbreaking new class of robotic tools for endoscopic surgery, announced today that nationally recognized healthcare entrepreneur and investor Robert Waggener has joined its Board of Directors. For decades, Waggener has earned a reputation in the healthcare industry as an innovator, a connector, and a leader of change and through change.

The Virtuoso Surgical Robotic System utilizes needle-sized robotic arms designed to significantly enhance the precision and dexterity of minimally invasive surgery performed via rigid endoscopes. Founded in 2016, Virtuoso Surgical is led by experts in surgical robotics, urologic surgery, engineering and AI, working together to transform patient outcomes by enabling surgeons to perform delicate procedures in previously inaccessible areas of the body.

Waggener joins the Virtuoso Surgical board at a pivotal time as the company conducted the first clinical use of its robotic surgical system in Hong Kong in May, and the FDA designated the device a Breakthrough Device under the 21st Century Cures Act in September. Virtuoso Surgical submitted a De Novo application to the FDA at the end of September, for marketing approval in the United States; that review process is expected to conclude in 2026, although review timelines are always uncertain.

Dr. Duke Herrell, Virtuoso Surgical CEO and urologic surgeon, stated, “It is a pleasure to welcome Rob Waggener to the Board of Directors of Virtuoso Surgical. Rob has had an incredible career in healthcare management across a broad spectrum of leadership at the hospital and corporate levels. Rob saw the early potential of Virtuoso Surgical to help an incredible number of patients and has not only been a supportive investor but a trusted mentor to our leadership team. The board is excited to have Rob join us, and we look forward to having his knowledge, experience and involvement in our strategic vision and planning as we move forward to regulatory approval, manufacturing, sales and clinical adoption.”

Robert Waggener stated, “In a sweeping era of disruption with AI and robotics, Virtuoso promises the holy grail for surgeons, patients and health systems: better outcomes, cost savings and time efficiencies. I’ve been involved with Virtuoso Surgical from the beginning and am excited about the company’s burgeoning commercial operations as we eagerly anticipate FDA marketing approval. This team, particularly Richard Hendrick as lead engineer, and Duke Herrell as CEO and CMO, have done a remarkable job developing this technology, as shown by their amazing clinical results in Hong Kong.”

For more than 35 years, Waggener has served in privately held, publicly traded, not-for-profit, for-profit, rural, urban, community-based, facility-centric, multi-state, large and small healthcare organizations. As a Licensed Clinical Social Worker and distinguished Fellow in the American College of Healthcare, Waggener has driven change in individuals and in organizations with a motto to “Keep Your Idealism Practical.” His ability to lead others to balance a passionate desire to serve with fiscal responsibility has helped him drive unprecedented change and growth, even in tumultuous times.

Waggener serves on multiple for-profit and not-for-profit Boards. In his last full-time role, he was Vice President of Addiction Services for Universal Health Services (UHS), a $14 billion hospital and healthcare company. Prior to that he was CEO of Foundations Recovery Network, a national, multi-site treatment company committed to serving adults and families struggling with co-occurring mental health and substance use disorders. He led Foundations for over 12 years through three acquisitions, while driving growth primarily through organic and de novo channels.

Waggener currently serves as Chairman of the Board of Promises Behavioral Health, a multi-state behavioral health company backed by private equity. He is co-owner with Michelle Klinedinst in ViaMar Health, an eating disorder treatment company in West Palm Beach, Florida. Waggener is also an investor, adviser and board member in several other start-up companies in the artificial intelligence/telehealth space. He spends a significant amount of time volunteering with not-for-profits in the behavioral health space. He and his wife, Liz, are actively engaged with philanthropy efforts in several arenas. Waggener is a speaker, writer, mentor, adviser and teacher.

About Virtuoso Surgical

Virtuoso Surgical has developed a groundbreaking robotic surgery system designed to radically improve minimally invasive rigid endoscopic surgery. The Virtuoso system features a pair of instrument delivery arms made of concentric nitinol tubes that mimic a surgeon’s hand motions to offer unprecedented control and dexterity to a full range of endoscopic applications. The system utilizes patented technology initially developed by Virtuoso’s founders at Johns Hopkins University, Vanderbilt University and Vanderbilt University Medical Center, with funding from the National Science Foundation and the National Institutes of Health. For additional information about Virtuoso Surgical, visit www.virtuososurgical.net. This device has not been approved by the U.S. Food and Drug Administration (FDA) and is not for sale in the United States.

U.S. Urology Partners Expands Footprint with Addition of Certain Assets of New Jersey Urology Central and South Divisions

U.S. Urology Partners announced today that New Jersey Urology’s central and south regions are joining its best-in-class, integrated urology services platform. With this affiliation, U.S. Urology Partners expands its geographic footprint into a seventh state, bringing the platform total to more than 70 offices, and welcomes one of the nation’s most respected urology groups while strengthening its position as the largest pureplay independent provider of urologic care in the U.S.

Serving patients in more than 20 locations throughout the central and southern regions of the state, the business was previously affiliated with Summit Health. As a partner to independent, community-based urology practices, U.S. Urology Partners enables these groups to focus on delivering premier care to the patients they serve. U.S. Urology Partners completed a strategic recapitalization with leading global investment firm General Atlantic in April 2025.

Corina Tracy, CEO of U.S. Urology Partners, stated, “We are honored to welcome the New Jersey Urology central and south divisions and their highly respected care team to U.S. Urology Partners. For decades, New Jersey Urology has been well-known for its leadership in the region, providing high-quality, compassionate care in convenient locations across the state along with expert clinical research capabilities. We look forward to working together in achieving our core purpose to provide the most effective, efficient and innovative urologic care in the communities we serve.”

Dr. Gordon A. Brown, New Jersey Urology, stated, “We are extremely proud to announce our new affiliation between the New Jersey Urology central and south divisions and U.S. Urology Partners, a nationally renowned urology platform dedicated to advancing patient care and practice excellence across the country. This partnership will allow our urologists to continue delivering exceptional, patient-centered care while gaining access to expanded clinical resources, operational support and opportunities for continued growth and innovation.”

New Jersey Urology central and south divisions include more than 20 locations in these counties: Atlantic, Bucks (PA), Burlington, Camden, Cumberland, Gloucester, Mercer, Middlesex, Monmouth and Somerset. See the locations and providers online at www.njurology.com.

U.S. Urology Partners helps urology practices of all sizes retain independence and deliver quality care while practicing medicine in their preferred community-based setting. U.S. Urology Partners supports its affiliated groups with expertise in business operations, data insights and technology infrastructure to drive improved patient outcomes and satisfaction and to alleviate the substantial administrative burdens that lead to meaningful dissatisfaction for many U.S. providers. U.S. Urology Partners also invests in end-to-end clinical capabilities for both cutting-edge genitourinary oncology, primarily cancer of the prostate, kidney and bladder, and non-oncology treatment pathways.

About U.S. Urology Partners

U.S. Urology Partners offers a comprehensive suite of practice management capabilities to its affiliated community-based urology practices, which maintain their local brand and identity that they have established, often over decades. U.S. Urology Partners currently supports six affiliated groups across a network of more than 70 locations in Florida, Indiana, Massachusetts, New Jersey, New York, Pennsylvania and Ohio. For more information, please visit www.us-uro.com and www.njurology.com.

Virtuoso Surgical Robotic System Receives FDA Breakthrough Device Designation

Virtuoso Surgical, Inc., a Nashville-based company developing a groundbreaking, entirely new class of robotic tools for endoscopic surgery, announced that the Virtuoso Surgical Robotic System has received FDA Breakthrough Device Designation for bladder lesion removal via en bloc excision, positioning the company at the forefront of early diagnosis and innovative bladder cancer care.

Leveraging a patented surgeon-controlled system that utilizes needle-sized robotic arms, the device is designed to significantly enhance the precision and dexterity of minimally invasive surgery performed via rigid endoscopes, a major component of the global endoscopy market. Virtuoso addresses a significant clinical need for improved specimen quality and staging in bladder lesions, the majority of which are bladder cancer.

“Virtuoso is unlike any surgical robot available today, and our overall vision is to provide surgeons with unprecedented dexterity and control in rigid endoscopic surgery, which is a distinct set of procedures and approaches that have not yet benefited from robotics. Virtuoso is starting with the removal of bladder lesions, the first critical step in diagnosing, staging and determining the management for cancerous lesions,” stated Virtuoso Surgical CEO and urologic surgeon Dr. Duke Herrell.

Effective Diagnosis Compared to Current Endoscopic Approaches

Founded in 2016, Virtuoso Surgical is led by experts in surgical robotics, urologic surgery, engineering and AI, working together to transform patient outcomes by enabling surgeons to perform delicate procedures in previously inaccessible areas of the body.

The en bloc resection (intact specimen) technique, enabled by the Virtuoso system, preserves the integrity of the pathological specimen and increases the accuracy of cancer staging, resulting in more definitive diagnoses versus the standard transurethral approach TURBT  (transurethral resection of bladder tumor). Recent randomized studies have shown that manually performed en bloc techniques can lower one-year cancer recurrence rates versus standard TURBT. However, the manual method is currently complex for surgeons to learn and perform, which limits widespread application in the U.S. and worldwide. With Virtuoso’s two instruments and robotic dexterity, the company aims to enable the widespread adoption of en bloc resection.

Recently, the Virtuoso robotic system facilitated a series of endoscopic bladder lesion excisions using the advanced en bloc technique performed by Dr. Jeremy Teoh, a world-renowned bladder cancer surgeon and researcher, at The Chinese University of Hong Kong (CUHK).

Dr. Jeremy Teoh commented, “The ability to perform an en bloc resection for bladder cancer with this level of robotic assistance is a game-changer even for an expert in the technique. This robotic approach has the potential to enable the widespread adoption of en bloc techniques, thereby minimizing local recurrence and providing a more definitive pathological specimen, which is crucial for guiding subsequent treatment decisions. We are extremely optimistic about what this technology means for the future of bladder cancer surgery and patient outcomes.”

FDA Breakthrough Devices Program Structure

The FDA Breakthrough Devices Program accelerates the development and review of medical devices that offer more effective diagnosis or treatment for life-threatening or irreversibly debilitating conditions. Qualifying technologies, such as Virtuoso Surgical’s system, benefit from prioritized regulatory interactions, more frequent feedback, and expedited assessment pathways to ensure rapid patient access once safety and effectiveness standards are met. This designation highlights the system’s potential to address critical gaps in bladder lesion removal and cancer care compared to current endoscopic approaches, such as TURBT.

Future Growth Plans

Virtuoso Surgical celebrates this significant milestone and looks forward to seeking FDA regulatory approval and partnering with clinicians to further validate the clinical advantages of its robotic platform through ongoing clinical studies and expanded patient access. Virtuoso has future plans to explore the use of this technology in urology and subsequently in various surgical specialties that utilize rigid endoscopic surgery, including gynecology, pulmonology, otolaryngology and neurosurgery.

About Virtuoso Surgical

Virtuoso Surgical has developed a groundbreaking robotic surgery system designed to radically improve minimally invasive rigid endoscopic surgery. The Virtuoso system features a pair of instrument delivery arms made of concentric nitinol tubes that mimic a surgeon’s hand motions to offer unprecedented control and dexterity to a full range of endoscopic applications. The system utilizes patented technology initially developed by Virtuoso’s founders at Johns Hopkins University, Vanderbilt University and Vanderbilt University Medical Center, with funding from the National Science Foundation and the National Institutes of Health. For additional information about Virtuoso Surgical, visit www.virtuososurgical.net. This device has not been approved by the U.S. Food and Drug Administration (FDA) and is not for sale in the United States.

Stacy Giles Named Chief Operating Officer of Greater Boston Urology

Greater Boston Urology announced today that Stacy A. Giles, MBA, has joined the organization as Chief Operating Officer. A seasoned leader with over 25 years of experience in healthcare administration and oncology, Giles assumes the role from Les Cavicchi, MPA, NHA, who is retiring after helping ensure the growth and success of Greater Boston Urology the last 12 years.

Greater Boston Urology is a market-leading, multi-specialty urology practice with convenient locations serving Greater Boston and the surrounding regions, including nine urology care centers and one interventional radiology center – and a second IR center opening in November. Operating throughout Massachusetts, Greater Boston Urology is the largest urology group within the state and maintains a longstanding history and track record of premier patient care and outcomes. Greater Boston Urology is an affiliate of U.S. Urology Partners, which supports community-based urology practices across the country and is backed by General Atlantic.

Mandy Lawrence, Chief Operating Officer of U.S. Urology Partners, stated, “We are pleased to welcome Stacy Giles to the Greater Boston Urology team and to express our appreciation for the many contributions of Les Cavicchi. We appreciate the commitment both have to Greater Boston Urology in providing world-class care that puts patients first. Greater Boston Urology is nationally recognized for its specialized urology services and urologic oncology care and will continue to grow across its multi-site clinical network, bringing the highest level of care and patient service to the community.”

Jonathan S. Brajtbord, M.D., Chair, Physician Clinical Council of Greater Boston Urology, said, “I am extremely excited to welcome Stacy Giles to our organization. She takes over for Les Cavicchi, who helped build and sustain Greater Boston Urology’s growth in the state as a leader in private practice urology. Stacy’s experience in healthcare operations and integration will be paramount to our vision of continued growth and providing our patients with the latest technology and urological services in the community. We are thrilled to have her at Greater Boston Urology.”

Stacy Giles, Chief Operating Officer of Greater Boston Urology, stated, “I am honored to join Greater Boston Urology, which is well-known for its culture of innovation and excellence, and the integrated care its nationally recognized team provides. What impresses me the most about Greater Boston Urology is its patient focus and commitment to providing a seamless patient experience through convenient locations providing specialized treatments with the utmost care and compassion. I look forward to building on Greater Boston Urology’s success to continue enhancing services that meet the needs of the community.”

Giles added, “Greater Boston Urology serves patients throughout the region for issues spanning from general urology, men’s health, women’s health and urogynecology, to advanced treatments for prostate, bladder, kidney and other urological cancers. Patients and referring physicians appreciate Greater Boston Urology’s comprehensive in-house services, including a state-of-the-art urology-specific laboratory, pathology, imaging, interventional radiology, surgery, clinical research and more. Greater Boston Urology will continue to be a trusted expert and partner, remaining on the forefront of urological care.”

Known for driving strategic growth, optimizing financial performance and leading high-impact initiatives, Giles has successfully overseen operations and large interdisciplinary teams across hospitals and health systems. Her expertise spans service line expansion, revenue generation, cost reduction and stakeholder engagement, with a proven ability to enhance patient outcomes and satisfaction. From launching comprehensive cancer programs to managing complex service lines and leading organizational transformation, Giles consistently delivers measurable results that strengthen market competitiveness and operational excellence.

Giles was previously on the senior leadership team of TidalHealth as Executive Director of the Cancer Institute, where she managed inpatient and outpatient services across multiple locations in Maryland and Delaware. Her background includes serving at UNC Health as Associate Vice President, Department of Medicine, where she directed operations of 600+ FTEs and eight service lines, including Oncology, Digestive, Palliative Care, Psychiatry and more, across 14 locations.

Giles began her career providing clinical support in medical oncology and oncology research, contributing to patient care and research outcomes. Giles received a Master of Business Administration, Leadership Emphasis, from Franklin University, where she earned her Bachelor of Science in Business Administration.

To learn more about Greater Boston Urology or to schedule an appointment with the care team, please visit www.GreaterBostonUrology.com or call 855.505.3335.

About Greater Boston Urology

Founded in 2010, Greater Boston Urology is an integrated urology practice. This medical model allows the practice to pool resources, resulting in more—and better—options for patients. From the moment a patient walks through the door, Greater Boston Urology strives to manage each patient’s care in-house. This in-house care includes imaging studies, diagnostic testing, pathologic testing, interventional radiology and surgical treatments. Supported by a talented team of urologists, urogynecologists, nurse practitioners and physician assistants, the practice has multiple care centers in Greater Boston, the South Shore and the Cape & Islands. To learn more, visit www.GreaterBostonUrology.com.

About U.S. Urology Partners

U.S. Urology Partners offers a comprehensive suite of practice management capabilities to its affiliated community-based urology practices, which maintain their local brand and identity that they have established, often over decades. U.S. Urology Partners currently supports five affiliated groups comprising over 180 providers across practices located in Florida, Indiana, Massachusetts, New York and Ohio. For more information, please visit www.us-uro.com.

Groundbreaking AI-Powered Prostate Cancer Treatment Optimization Tool Now Available at Associated Medical Professionals of NY

Associated Medical Professionals (A.M.P.) announced today the availability of the ArteraAI Prostate Test, an AI-powered risk stratification tool to help personalize and optimize treatments for patients with localized prostate cancer. Dr. Steven E. Finkelstein, National Director of the Center of Advanced Radiation Excellence (CARE) for U.S. Urology Partners and Director Radiation Oncology Research, helped in the development of the tool and was instrumental in its approval process.

“We were excited to be the first in New York to order the ArteraAI Prostate Test for our patients with prostate cancer. Cancer is a scary diagnosis for any patient, but with this new test, we can personalize care and help ensure that the treatments we prescribe will lead to the best outcomes,” said Dr. Steven E. Finkelstein. “The low cost and fast turnaround of the test make it much more accessible for patients while providing physicians with advanced information to identify optimal treatment plans.”

Prostate cancer is the second-leading cause of cancer death in American men, behind only lung cancer. Prostate cancer is a serious disease, but most men diagnosed with prostate cancer do not die from it. More than 3.5 million men in the United States who have been diagnosed with prostate cancer are still alive today, according to the American Cancer Society. Because of the variability in prostate cancer aggressiveness, a major challenge facing clinicians and patients is determining the right treatment options, as both under- and over-treatment can be an issue.

The ArteraAI Prostate Test is the only test in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer. The ArteraAI Prostate Test can increase patients’ confidence by offering more clarity around whether they will benefit from a specific treatment course.

Dr. Christopher M. Pieczonka, CEO of Associated Medical Professionals of NY,  stated, “The use of multimodal artificial intelligence (MMAI – Artera) is a game changer for New York State patients. This is the only test that has prostate cancer specific mortality as a prognostic endpoint in localized prostate cancer, which enables us to identify the most beneficial treatment plans and provide the highest level of care to our patients.”

Artera’s multimodal artificial intelligence biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular prostate cancer therapy and has been validated using many Phase 3 randomized trials.

About Associated Medical Professionals of NY (A.M.P.)

Associated Medical Professionals of New York (A.M.P.) is a medical practice based in Syracuse serving the Central New York region. Established in 2008, A.M.P. has grown to become one of the largest groups of its kind in the area with nine offices and services at 13 hospitals. As a pivotal point of care in each community, A.M.P. is able to provide continuity of care for a vast population of patients. A.M.P. maintains a robust suite of services, including advanced urological care, robotic surgery, cancer care, radiation oncology,  interventional radiology, pathology, lithotripsy, imaging and clinical research. For more information about A.M.P., visit www.ampofny.com.

About U.S. Urology Partners

U.S. Urology Partners offers a comprehensive suite of practice management capabilities to its affiliated community-based urology practices, which maintain their local brand and identity that they have established, often over decades. U.S. Urology Partners currently supports five affiliated groups comprising over 180 providers across practices located in Florida, Indiana, Massachusetts, New York and Ohio. For more information, please visit www.us-uro.com.

About Artera

Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test. Artera’s laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera’s laboratory in Jacksonville, Florida, and can be ordered online at www.artera.ai.

U.S. Urology Partners Appoints Three Executives to C-Suite, Positions for Accelerated Growth

U.S. Urology Partners today announced the addition of three experienced executives to its leadership team, supporting the company’s continued rapid growth. As a partner to independent, community-based urology practices, U.S. Urology Partners enables them to focus on delivering premier care to the patients they serve and is backed by leading global investor General Atlantic.

Reinaldo “Rey” Pascual joins U.S. Urology Partners as Chief Financial Officer and Trip Cothren as Chief Strategy and Integration Officer, while Kiersten O’Hara is promoted to Chief People Officer.

Corina Tracy, Chief Executive Officer of U.S. Urology Partners, stated, “These strategic appointments come at a pivotal time as U.S. Urology Partners deepens its presence and capabilities across its existing markets while expanding into new geographies through affiliating with leading urology practices that share our vision. We are pleased to welcome Rey Pascual, Kiersten O’Hara and Trip Cothren to the U.S. Urology Partners leadership team. Their experience and commitment will help U.S. Urology Partners deliver on its purpose of supporting urology practices in providing an individualized, high-quality and compassionate patient experience for every person we are honored to serve.”

U.S. Urology Partners helps urology practices of all sizes retain independence and deliver quality care while practicing medicine in their preferred community-based setting. The company supports its affiliated groups with deep expertise in business operations, data insights and technology infrastructure to drive improved patient outcomes and satisfaction and to alleviate the substantial administrative burdens that lead to burnout for many providers. U.S. Urology Partners also invests in end-to-end clinical capabilities for both cutting-edge genitourinary oncology – primarily cancer of the prostate, kidney and bladder – and non-oncology treatment pathways.

Reinaldo “Rey” Pascual, Chief Financial Officer

Pascual is an accomplished financial professional with years of experience in investment banking, private equity and venture capital. As Chief Financial Officer, Pascual leads U.S. Urology Partners’ financial organization and oversees its capital deployment strategy, both organically and via mergers and acquisitions. Pascual was most recently a healthcare investor at General Catalyst, where he supported late-stage growth investments. He also served as a member of the healthcare team at General Atlantic, where he led investment efforts and advised portfolio companies on financial strategy and M&A execution. He began his career in investment banking at Centerview Partners and holds a B.A. in Economics from Harvard College. Learn more at www.us-uro.com/reinaldo-rey-pascual.

Kiersten O’Hara, Chief People Officer

O’Hara is an experienced human resources professional dedicated to the dynamic and mission-driven healthcare industry. She was previously VP of People Operations at U.S. Urology Partners and also served as HR Director at affiliate practice Urology of Indiana, where she played a leadership role for eight years shaping the organization’s culture, driving strategic workforce initiatives and aligning HR practices with long-term business goals. O’Hara earned her bachelor’s degree from Purdue University and holds a master’s degree in organizational communication from Indiana University-Purdue University Indianapolis. Her certifications include Society for Human Resources Management – Senior Certified Professional and Certified Predictive Index Practitioner. Learn more at www.us-uro.com/kiersten-ohara.

Trip Cothren, Chief Strategy and Integration Officer

Cothren leads growth and integration efforts across the U.S. Urology Partners national platform, with a focus on expanding the provider network, enhancing ancillary services and driving operational excellence. He brings years of healthcare leadership experience in strategy, implementation and business development. Cothren most recently served as Vice President of Market Implementation at agilon health, where he led large-scale implementations across new value-based care partnerships. He also held positions with Privia Health and Accenture centered around technology integrations, financial planning and strategic design. He holds a B.E. in Biomedical Engineering from Vanderbilt University. Learn more at www.us-uro.com/trip-cothren.

More detailed information about the U.S. Urology Partners leadership team can be found at www.us-uro.com/our-team.

About U.S. Urology Partners

U.S. Urology Partners offers a comprehensive suite of practice management capabilities to its affiliated community-based urology practices, which maintain their local brand and identity that they have established, often over decades. U.S. Urology Partners currently supports five affiliated groups comprising over 180 providers across practices located in Florida, Indiana, Massachusetts, New York and Ohio. For more information, please visit www.us-uro.com.